BioSpace News Archive

Business

Appendix 4C Quarterly Activity ReportMesoblast Financial and Operational Highlights for Quarter Ended March 31, 2023

Mesoblast Limited, global leader in allogeneic cellular medicines for inflammatory diseases, provided an activity report for the third quarter ended March 31, 2023.

April 27, 2023
·
8 min read
Biotech Bay

Daewoong Pharmaceutical announces a Global License Agreement for DWP213388, a new drug candidate for autoimmune disease with Vitalli Bio

Daewoong Pharmaceutical announced that it had signed a Global License Agreement for its autoimmune disease drug candidate DWP213388 with Vitalli Bio, a US biotechnology company, on April 28.

April 27, 2023
·
5 min read
BioCapital

CEL-SCI Announces $1.35 Million Underwritten Confidentially Marketed Public Offering of Common Stock

CEL-SCI Corporation, a Phase 3 cancer immunotherapy company, announced the pricing of its underwritten confidentially marketed public offering of 794,117 shares of common stock at an offering price of $1.70 per share.

April 27, 2023
·
4 min read
Pharm Country

Hillstream BioPharma Announces Pricing of Public Offering - April 28, 2023

Hillstream BioPharma, Inc. announced the pricing of an underwritten public offering of 5,300,000 shares of its common stock.

April 27, 2023
·
4 min read
FDA

FDA Approves Otsuka and Lundbeck’s ABILIFY ASIMTUFII® (aripiprazole), the First Once-Every-Two-Months Long-acting Injectable (LAI) for the Treatment of Schizophrenia or Maintenance Monotherapy Treatment of Bipolar I Disorder in Adults

Otsuka America Pharmaceutical, Inc. and Lundbeck announce the U.S. Food and Drug Administration has approved the New Drug Application for ABILIFY ASIMTUFII® extended-release injectable suspension for intramuscular use, a once-every-two-months injection for the treatment of schizophrenia in adults or for maintenance monotherapy treatment of bipolar I disorder in adults.

April 27, 2023
·
14 min read